Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380390 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
A Phase 4 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT03380390: Completed Phase 4 study, sponsored by Aclaris Therapeutics.
NCT03380390 is a Phase 4 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03380390, a Phase 4 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.
Primary Outcome
An AE is defined as any untoward medical occurrence in a clinical study participant administered a medicinal product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not it is related to the medicinal (investigational) product. An SAE is any untoward medical occur
Interventions
- DRUG Oxymetazoline HCL 1.0% Cream
- DEVICE Energy-Based Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 4 |
What the finished NCT03380390 record still lists
NCT03380390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxymetazoline HCL 1.0% Cream is the first listed.
NCT03380390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03380390 about?
NCT03380390 is a clinical study titled "Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea". This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.
What is the current status of trial NCT03380390?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2017-12-04. Estimated completion is 2018-06-15.
What interventions are being tested in trial NCT03380390?
The interventions under investigation include: Oxymetazoline HCL 1.0% Cream (DRUG), Energy-Based Therapy (DEVICE).
Who is sponsoring clinical trial NCT03380390?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03380390's enrollment target sits among peer trials
46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI